- ABOUT CARLYLE
- Corporate Overview
- The Carlyle Edge
- Geographic Reach
- Portfolio Employees Map
- Industry Awards
- Corporate Videos
- Carlyle FAQ
Who We AreOur firm is global.Our expertise is deep.Our products are diverse.We work for our investors.We form partnerships.We invest wisely.We create value.
- OUR BUSINESS
We believe that being a good corporate citizen is good business practice and creates long-term value for our investors.
- MEDIA ROOM
- PUBLIC INVESTORS
- CREATING VALUE
Dr. Robert Easton is a Managing Director and Fund-head of Carlyle Ireland. Previously, he was Co-head of Carlyle Europe Technology Partners, a fund focussed on European growth capital and buyout opportunities in a variety of sectors including media, software, telecom, aerospace and defense, healthcare and technology. Prior to that, Dr. Easton headed-up Carlyle’s Buyout team in the UK. He is based in London and has been with Carlyle for 14 years, has sat on multiple portfolio company boards and led a number of different teams of investment professionals.
Since joining Carlyle in 2000, Dr. Easton has worked in both Europe Buyout and Europe Technology and has also been involved with a number of cross-fund transactions at Carlyle in the United States and Japan. He has sector expertise in chemicals, advanced materials, renewables, aerospace and defence, media, software and TMT.
Prior to joining Carlyle, Dr. Easton was Vice President of Corporate Development at Invensys plc with responsibility for the execution of acquisitions and disposals. Dr Easton was a key figure in the mid-nineties transformation of BTR from a diversified conglomerate to a focused engineering group and, following the merger of BTR and Siebe to form Invensys in 1999, in the further focusing of Invensys to become a leading Automation and Controls group. During this period of substantial change, he executed a total of 35 acquisitions and disposals with an aggregate value of €7 billion.
Dr. Easton joined BTR in 1996 from Trafalgar House, another major UK engineering group where he was Director of Corporate Finance and Planning with responsibility for strategic planning and acquisitions and disposals. Prior to becoming a corporate development executive, Dr. Easton spent eight years in the investment banking business working initially for CSFB and then for a period of five years for Wasserstein Perella, a mergers and acquisitions specialist boutique
Dr. Easton has a first class honors degree in chemistry from Imperial College in London and a Doctorate in organic synthesis from Oxford University.
Dr. Easton has been registered with the FSA since 2001, and is currently registered for the CF10, CF11, CF3 and CF30 controlled functions. In addition to his Directorships of Carlyle portfolio companies, Dr. Easton is a past Chairman of the British Venture Capital Association, a founding Director of Walker Guidelines Monitoring Group for private equity disclosure and a member of the Advisory Board of the Imperial College Business School.